Previous studies have suggested that differences in the ability of normal and malignant cells to process certain alternatively spliced pre-mRNA transcripts can be exploited as a potentially powerful means of targeting the expression of therapeutic genes to tumor cells in vivo and in vitro. Specifically, it was shown that efficient processing of minigene constructs containing the alternatively spliced CD44 exons v9 and v10 only occurs in tumor cells that express CD44 isoforms that incorporate these exons (e.g. CD44R1). In the present study, efforts were made to define the molecular mechanisms that underlie the apparent specificity of this process. RT-PCR analysis and DNA sequencing were used to characterize the various splicing events that occur between CD44 exons v8, v9 and v10 following transfection of minigene constructs containing these various exons into CD44R1-positive (PC3) and CD44R1-negative (T24) cell lines. The results obtained confirm that although the v8-v9 intron is efficiently removed in both CD44R1-positive and CD44R1-negative cells, the corresponding v9-v10 intron is accurately spliced and the exons appropriately joined only in lines that express v10-containing CD44 isoforms (e.g. PC3). In CD44R1-negative cell lines (e.g. T24) alternative 5 0 and 3 0 splice sites located within the v9-v10 intron are preferentially used, resulting in various portions of the intron being retained within the final processed mRNA product. It is proposed that identification of these functionally important intronic sequence elements will facilitate the development of second generation ''splice activated gene expression'' vectors that may prove useful in various cancer gene therapy applications.
T he safety of gene therapy-based approaches to the treatment of cancer would be greatly enhanced if simple and reliable means could be developed to restrict the expression of putative therapeutic genes to particular cell types or tissues in vivo. While encouraging results in this regard have been obtained using viral or other vectors with restricted cellular tropism, 1 or by placing the gene of interest under the control of an appropriate promoter/ enhancer element, 2 there is a clear need for further improvement if gene therapy is to gain wide acceptance as a modality in the treatment of cancer. 3 Among a number of recently developed approaches that have shown particular promise, we have demonstrated that alternative splicing constitutes a potentially powerful means of targeting therapeutic genes to cells that possess certain differentially expressed phenotypic characteristics. 4 Splicing is the process by which intronic sequences are removed from an initial pre-mRNA transcript generated by RNA polymerase II and the exons assembled to give a contiguous message that then undergoes translation to produce the corresponding protein product. 5 Splicing can be either constitutive, where all potential exons are included in the final transcript, or alternative, if particular exons are included or excluded in a developmentally regulated, activation-dependent and/or cell-specific manner. 5, 6 The adhesion protein CD44 exemplifies the complex nature and functional importance of alternative splicing. The human CD44 gene, which is located on the short arm of chromosome 11, is composed of 20 exons and includes a contiguous stretch of 10 exons (v1-v10) that undergo extensive alternative splicing, potentially generating as many as a thousand different isoforms that contain additional sequences of varying length inserted into a common site in the extracellular domain of the molecule proximal to the membrane spanning region. 7, 8 Among the two most important isoforms are CD44 H, which lacks any of the alternatively spliced exons, and CD44R1, which includes sequences encoded by the alternatively spliced exons v8, v9 and v10. 7 While CD44 H is expressed primarily on resting normal cells, CD44R1 is generally restricted to a subset of transformed cells and certain activated normal cells. 7, 9, 10 Importantly, striking correlations have been noted between the expression of CD44R1 on tumor cells and both enhanced metastatic propensity and poor patient prognosis. 7, 8, 10 While the precise molecular mechanisms that underlie this relationship remain to be fully defined, studies from our group have shown that unlike CD44 H, CD44R1 can promote cell-cell adhesion via the recognition of chondroitin sulfate side chains, particularly if these are presented on the surface of opposing cells in association with other CD44R1 molecules. 11 Recently, we have extended these studies and demonstrated that differential alternative splicing of CD44 can also be exploited in the context of tumor-targeted gene therapy. 4 Specifically, we have developed a series of ''splice-activated gene expression'' (pSAGE) vectors that contain minigene constructs in which a putative therapeutic gene is linked to two or more CD44 exons along with their corresponding introns such that expression of a chimeric protein incorporating the gene of interest can only occur if the intronic sequences are completely and accurately removed from the transcript that is produced. We have evaluated this approach using alkaline phosphatase (ALP) as a model therapeutic gene. ALP expression can be readily detected in transduced target cells by staining with the substrate BCIP/INT, while the ability of the enzyme to dephosphorylate the inactive prodrug Etopophos s , generating the potent topoisomerase II inhibitor etoposide, can be exploited in a GDEPT strategy.
The results obtained in these studies indicate that while pSAGE constructs containing the v8-v9 intron appear to be appropriately spliced in both CD44R1-positive and CD44R1-negative cells, the v9-v10 intron is accurately removed only in cells that express CD44R1. No ALP activity can be detected in CD44H-positive cells transduced with constructs containing the v9-v10 intron although the chimeric protein is stable and functional in these cells as determined by transfection of the corresponding cDNA. These data suggest that the v9-v10 intron constitutes a crucial control point in the regulation of CD44 splicing and raise the possibility that the unique ability of CD44R1-positive cells to mediate the appropriate splicing event could potentially be exploited in the development of tumor-targeted gene therapy. At present, however, the molecular mechanisms that underlie the apparent specificity of v9-v10 splicing in CD44R1-positive cells are unclear. Understanding the nature of such mechanisms is essential if one is to produce compact vectors, devoid of extraneous and potentially problematic sequences, that behave in a predictable manner in broad range of cell lines in the context of various therapeutic genes.
As an initial step toward this goal, in the present study CD44R1-positive (PC3) and CD44R1-negative (T24) cell lines were transfected with pSAGE constructs containing two or more of the alternatively spliced CD44 exons v8, v9 and v10 along with their corresponding introns, and the spectrum of splicing events that occur between the various exons determined by RT-PCR analysis and direct sequencing of the amplified products. As one would expect based upon characterization of ALP expression, the results obtained confirm that the v8-v9 intron is efficiently spliced in all cell types examined irrespective of CD44 isoform expression. In contrast, the v9-v10 intron appears to be accurately removed and the exons appropriately joined only in cell lines that express v10-containing CD44 isoforms (e.g. PC3). In CD44R1-negative cell lines (e.g. T24) alternative 5 0 and 3 0 splice sites located within the v9-v10 intron are preferentially used resulting in various portions of the intron being retained within the final processed mRNA product. Since the retained intronic sequences contain multiple stop codons in all three reading frames, translation is prematurely terminated at this point and no functional protein is produced. These results help explain the apparent targeting specificity of splice-activated gene expression and suggest ways in which the design of pSAGE vectors can be further improved.
Materials and methods

Cell lines
The prostate adenocarcinoma cell line, PC-3, 12,13 and the urinary bladder transitional carcinoma cell line, T24, 14 were obtained from the American Type Culture Collection (ATCC, Rockville, MD). Both cell lines were cultured in Dulbecco's minimum essential medium (DMEM) (Life Technologies Inc., Grand Island, NY) supplemented with 10% fetal bovine serum (FCS; Sigma, St Louis, MO), 1000 U/ml penicillin-streptomycin (Life Technologies Inc.) and 0.3 mg/ml L-glutamine (Mediatech-Cellgro, Herndon, VA) (DMEM þ 10% FCS) at 371C in an atmosphere containing 5% CO 2 .
Construction of pSAGE vectors
The construction of the pSAGE vectors v8-v9.ALP and v9-v10.ALP and the corresponding cDNA controls v8/ v9.ALP and v9/v10.ALP has been described in detail previously. 4 A similar procedure was used to create the v8-v9-v10.ALP construct. Briefly, a fragment containing the CD44 v8-v9-v10 region, including the intron sequences located between v8-v9 and between v9-v10, was amplified from genomic DNA by PCR using the following primer pair:
. A PCR product of approximately 3.3 kb was isolated, digested with ClaI and XhoI and cloned into the ClaI-XhoI site of plasmid pBS.CD44L. 4 A leaderless ALP fragment was then added to the 3 0 end of this construct exactly as previously described. 4 A slightly modified procedure was used to generate v8/v9-v10.ALP, a construct in which the v8 and v9 exons are already joined together and only the intron between v9 and v10 remains. Briefly, the v8/v9 (no intron) and the v9-v10 (intron containing) PCR products obtained as previously described 4 were ligated together and used as a template for a PCR reaction employing the v8-5 0 and v10-3 0 primers indicated above. A PCR product of approximately 1.7 kb was isolated, once again digested with ClaI and XhoI and cloned into the ClaI-XhoI site of plasmid pBS.CD44L. 4 A leaderless ALP fragment was then added to the 3 0 end of this construct exactly as previously described. 4 A control v8/v9/v10.ALP cDNA vector lacking intronic sequences was generated via the same basic procedure but using the CD44R1 cDNA clone pCDM8.CD44R1 cl2.3 9 as template in the PCR reactions. Ultimately, all pSAGE constructs were subcloned into the episomal EBV-based expression vector pCEP4 (Invitrogen). The ''empty'' pCEP4 vector and pCEP4 containing the full-length ALP cDNA (pCEP4.ALP) 15 were used respectively as negative and positive controls.
Transfection of T24 and PC3 cells
The various pSAGE constructs were introduced into T24 and PC3 cells by electroporation. Log phase cells were harvested by gentle trypsinization, resuspended in DMEM þ 10% FCS and pelleted by centrifugation. Cells were washed once in PBS and resuspended at approximately 2 Â 10 7 cells/ml in PBS. Aliquots of the cell suspension (400 ml) were mixed with 20 mg plasmid DNA purified using the Qiagen Midi Prep DNA Isolation Kit (Qiagen; Valencia, CA) and transferred to a 2 mm gap electroporation cuvette (BTX; San Diego, CA). Samples were incubated on ice for 10 minutes before being electroporated at 280 V, capacitance setting 325 mF, resistance R3 (48 O) using a BTX600 electroporator (BTX). The time constants obtained were generally around 4.5 milliseconds. The contents of each cuvette were immediately resuspended in 30 ml prewarmed DMEM þ 10% FCS and plated in a 15 cm Integrid tissue culture dish (Nalge Nunc International; St. Louis, MO). At 24 hours after electroporation, Hygromycin B (Sigma) was added at a final concentration of 250 mg/ml and the plates incubated for a further 2 weeks to allow selection of tranfectants. For analysis of ALP expression and alternative splicing events, groups of at least 100 colonies were pooled and expanded in DMEM þ 10% FCS containing 250 mg/ml Hygromycin B.
Staining of pSAGE transfectants for ALP expression
The expression of ALP by transfected cells was determined by staining with the colorimetric substrate, BCIP/ INT (Moss Inc., Pasadena, MD). Cell lines were grown on tissue culture treated coverslips (Nalge Nunc International) for 24 hours after which time the culture medium was removed and cells washed twice with HBSS. Coverslips were fixed with ethanol for 20 seconds and subsequently equilibrated in HBSS for 3 minutes. Longer fixation was avoided as this abrogated the enzymatic activity of ALP. Filtered BCIP/INT was added to the coverslips and developed for approximately 30 minutes. Cells were washed once with distilled H 2 O before being counterstained with hematoxylin (Sigma). Coverslips were fixed onto slides using Gel/Mount (Biomeda, Foster City, CA) and photographed on an inverted-phase microscope.
RT-PCR analysis of alternatively spliced pSAGE-derived transcripts produced in T24 and PC3 cells mRNA was isolated from T24 and PC3 cell lines transfected with each of the pSAGE constructs and RT-PCR was performed to identify the nature of the splicing events that occur in each cell line. Briefly, mRNA was isolated from pools of at least 100 T24 and PC3 colonies stably expressing their respective pSAGE constructs using the Oligotex Purification of Poly A þ RNA Kit (Qiagen). Purified mRNA samples were digested with amplification grade deoxyribonuclease I (DNAse I; Life Technologies Inc.) for 15 minutes at room temperature to ensure complete removal of any contaminating plasmid or genomic DNA. The DNAse I was subsequently inactivated by incubation at 651C for 15 minutes after the addition of EDTA (2 mM final; Life Technologies Inc.). The purified mRNA was used to produce cDNA with the First Strand cDNA Synthesis Kit (Amersham Pharmacia Biotech, Piscataway, NJ) and was amplified by PCR in a Thermocycler (Omnigene; Cambridge, MA). A standard optimized cycle (951C for 30 seconds, 571C for 30 seconds, 721C for 4 minutes, 30 cycles) was used for each reaction employing a 5 0 CD44 leader primer (5 0 -GCTCTAGACGCTCCGGACACC-3 0 ) and a 3 0 ALP primer (5 0 -GCTTGGTCTCGCCAGTACTTGG-3 0 ). The various splicing products were resolved by running 5 ml of each PCR reaction on a 1% agarose/TAE gel.
Subcloning and sequencing of alternatively spliced pSAGE-derived transcripts produced in T24 and PC3 cells
The various splicing products generated from the pSAGE constructs were cloned into pBluescript for subsequent sequence analysis. Briefly, whole RT-PCR reactions from each pSAGE-transfected T24-and PC3-cell line were Geneclean purified (Bio101; Carlsbad, CA), T4 polymerase filled (Life Technologies Inc.), and ligated into the Eco RV digested pBluescript KS þ . Clones were screened for inserts of the appropriate size(s) and examples of each major product were sequenced by SeqWright (Houston, TX). Sequences were aligned using Gene Construction Kit-2 (GCK-2) software (Textco, West Lebanon, NH).
RT-PCR analysis of CD44 intron retention in T24 and PC3 cells
Poly A þ mRNA was isolated from log phase T24 and PC3 cells and cDNA synthesized as described above. To determine whether portions of the v8-v9 and/or v9-v10 intron are retained within the primary CD44 transcripts expressed by these cells, PCR analysis was carried out as described above using 5 0 and 3 0 primers that anneal respectively to CD44 exon v8 (5 0 -GCAGTCATAGTACAACGC-3 0 ) and v10 (5 0 -GCTTTCCTTCGTGTGTGG-3 0 ). The pCEP4.CD44R1 plasmid was used as a control template to indicate the expected size of the appropriately spliced product in which all intronic sequences are removed. The various splicing products were resolved by running 5 ml of each PCR reaction on a 1% agarose/TAE gel.
Western blot analysis
T24 and PC3 cells were harvested by brief incubation in cell dissociation solution (Sigma, St Louis, MO), washed twice with PBS, and resuspended at 2 Â 10 7 cells/ml in PBS containing 1% (v/v) Nonidet P-40 (Sigma), 1mM EDTA, 150 mM NaCl, and 10 mM Tris (pH 7.4). Cell lysates were incubated on ice for 15 minutes with repeated vortexing, and then centrifuged for 10 minutes to pellet nuclei and other cellular debris. Supernatants were aliquoted and stored at À801C until required.
SR-Protein blots. Cell lysates were rapidly thawed, mixed with an equal volume of 2 Â nonreducing sample buffer (250 mM Tris, 20% (v/v) glycerol, 8% (w/v) SDS (pH 6.8) and 10% (w/v) bromophenol blue) and incubated at 801C for 10 minutes. Total cellular proteins were separated by SDS-PAGE using an XCell Mini-Cell electrophoresis system (Invitrogen, Carlsbad, CA) and transferred onto PVDF membranes (Bio-Rad, Richmond, CA). Filters were blocked overnight at 41C in PBS containing 0.01% (v/v) Tween 20, 2.5% (w/v) BSA, 2.5% (w/v) skim milk powder, and 0.2% (w/v) glycerol 2-phosphate (Sigma). After several washes with PBS containing 0.01% Tween 20, 0.5% skim milk powder, 0.5% BSA and 0.2% glycerol 2-phosphate (PBS-Tween), the filters were incubated with a 1:1000 dilution of the mouse anti-SR protein mAb 1H4 (Zymed Laboratories, San Francisco, CA). After 2 hours at room temperature, the membranes were washed (4 Â 5 minutes) in PBSTween then incubated for a further 2 hours at room temperature with a 1:5000 dilution of peroxidase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). After extensive washing, proteins were visualized using the ECL Western Blotting Analysis System (Amersham Biosciences; Buckinghamshire, England) and Kodak Biomax MR imaging film.
hnRNP A1 blots. Cell lysates were rapidly thawed, mixed with an equal volume of 2 Â NuPAGE LDS sample buffer (Invitrogen), then incubated at 801C for 10 minutes. Total cellular proteins were separated on NuPAGE 10% Bis-Tris gels (Invitrogen) using an XCell Mini-Cell electrophoresis system (Invitrogen) and transferred onto PVDF membranes (Bio-Rad, Richmond, CA). Membranes were blocked overnight at 41C in PBS containing 0.01% (v/v) Tween 20 and 5% (w/v) skim milk powder. After several washes with PBS containing 0.01% Tween 20 and 1% skim milk powder, the filters were incubated with a 1:1000 dilution of mouse anti-hnRNP A1 mAb 9H10 (Abcam Inc; Cambridge, MA). After 2 hours at room temperature, membranes were washed and further processed as described above.
Results
Splicing of pSAGE minigene constructs in CD44R1-positive (PC3) and CD44R1-negative (T24) tumor cell lines
A family of pSAGE vectors were generated in which various combinations of the alternatively spliced CD44 exons v8, v9 and v10 with or without their corresponding introns were cloned in-frame between the CD44 leader sequence and a leaderless ALP cDNA such that expression of a chimeric protein incorporating both the CD44 exons and ALP required accurate and complete removal of the intronic sequences from the initial pre-mRNA transcript (Fig 1) . The various constructs were cloned into the EBV-based episomal expression vector pCEP4 and the plasmids introduced into the CD44R1-positive cell (Fig 2) . Strong ALP activity is also evident in both CD44R1-positive PC3 cells and CD44R1-negative T24 cells transfected with the v8-v9.ALP genomic construct suggesting that this particular intron is constitutively removed irrespective of which CD44 isoform is expressed by the target cell population. In contrast, the v9-v10.ALP genomic construct appears to be differentially processed. While strong ALP activity is evident upon introduction of the minigene into CD44R1-positive PC3 cells, no activity is seen in similarly transfected CD44R1-negative T24 cells (Fig 2) . These data suggest that the v9-v10 intron is accurately and completely removed only in CD44R1-positive cells. Supporting this assertion, no ALP activity is seen in T24 cells transfected with either the v8-v9-v10.ALP or v8/v9-v10.ALP constructs, presumably because the v9-v10 intron or portions thereof (see below) are retained in the final mRNA transcripts derived from these sequences. Strong ALP activity is, of course, evident in similarly transfected PC3 cells as these cells seem capable of accurately splicing the v9-v10 intron (Fig 2) .
Characterization of the splicing events that occur in PC3 and T24 cells transfected with v8-v9.ALP or v9-v10.ALP pSAGE constructs
RT-PCR was used to better characterize the major splicing events that occur between the CD44 v8-v9 and v9-v10 introns in PC3 and T24 cells transfected with the corresponding pSAGE vectors. Briefly, mRNA isolated from cells transfected with v8-v9.ALP or v9-v10.ALP constructs was reverse transcribed and used as a PCR template together with primers specific for the CD44 leader sequence and the 5 0 end of the alkaline phosphatase gene. This particular primer pair will amplify only products encoded by the corresponding pSAGE vectors and not those arising from the endogenous CD44 gene. Plasmid DNA was used as a control to illustrate the expected size of the corresponding unspliced pre-mRNA transcript. mRNA isolated from cells transfected with v8/ v9.ALP or v9/v10.ALP cDNA control constructs was similarly used to illustrate the size of the fully spliced products.
In concordance with the ALP expression data shown in Figure 2 , the only PCR product observed in both T24 and PC3 cells transfected with the v8-v9.ALP genomic DNA construct appeared identical in size (335 bp) to that seen in cells transfected with the v8/v9.ALP cDNA control (Fig 3) . These data suggest that both T24 and PC3 cells are capable of efficiently and accurately splicing the v8-v9 intron. Confirmation of this conclusion was obtained by isolating and subcloning the PCR products obtained and fully sequencing a number of representative clones (data not shown).
The splicing products produced in T24 and PC3 cells transfected with the v9-v10.ALP construct were also examined by RT-PCR as described above. Once again plasmid DNA was used as a control to illustrate the expected size of the unspliced transcript while mRNA isolated from cells transfected with v9/v10.ALP cDNA control was used to indicate the size of the fully spliced cDNA product. As shown in Figure 3 , T24 cells transfected with the v9-v10.ALP construct generated two major and one minor RT-PCR products, none of which was of the size expected for the appropriately spliced transcript (434 bp). The upper minor band appears similar in size to the completely unspliced genomic DNA template (1.8 kb), while the other two species are 832 and 561 bp, respectively. All three RT-PCR products were subcloned and sequenced. The 1.8 kb species indeed corresponds to the unspliced template and contains the entire v9-v10 intron, while the 832 bp and 561 bp products appear to have retained various proportions of the intron (Fig 4a and b) . By reference to the complete v9-v10 intronic sequence, it is clear that the 832 bp product is produced by a splicing reaction in which the 5 0 splice site located at the end of exon v9 is joined to an alternative 3 0 splice site located within the v9-v10 intron (Fig 4a) . The 561 bp product is similarly generated by a splice reaction in which an alternative 5 0 splice site located within the v9-v10 intron is joined to the 3 0 splice site found at the 5 0 end of exon v10 (Fig 4b) . The intronic sequences retained within both the 832 and the 561 bp product contain multiple stop codons in all three reading frames explaining the absence of ALP expression in T24 cells transfected with the v9-v10.ALP construct (Fig 2) .
Two major RT-PCR products are seen in PC3 cells transfected with the v9-v10.ALP construct (Fig 3) . The lower 434 bp species is identical in size to the major product obtained in cells transfected with v9/v10.ALP cDNA control (Fig 3) . Sequence analysis confirmed that this species indeed represents an appropriately spliced transcript in which the v9-v10 intron was completely and accurately removed. The larger 832 bp species is similar in size to one of the three products obtained in T24 cells. Sequence analysis confirmed the identity of the two products indicating that this species was generated by a splicing reaction in which 5 0 splice site located at the end of exon v9 is joined to an alternative 3 0 splice site located within the v9-v10 intron (Fig 4a) . Thus, unlike the v8-v9 intron, which is constitutively spliced in both T24 and PC3 cells, the v9-v10 intron appears to be appropriately spliced only in CD44R1-positive PC3 cells.
Intron retention within endogenous CD44 transcripts
It is important to determine whether the aberrant splicing events that occur between exons v9 and v10 in transcripts derived from pSAGE vectors also occur in endogenous CD44 transcripts, as the presence of retained intronic sequences within such mRNAs may help identify the subset of tumors that can be most effectively targeted using the proposed splice activated gene expression approach. As shown in Figure 5 , RT-PCR analysis using analysis revealed the presence in these cells of low levels of CD44 transcripts containing sequences derived from exon v8-v10. While a proportion of these transcripts are appropriately spliced, a number of larger products, that presumably retain portions of v8-v9 and/or v9-v10 intron, are also seen (Fig 5) . The two major species (arrowed in Fig 5) are of the size expected if the alternative intronic splice donor and acceptor sites identified in the context of pSAGE vectors are utilized.
Analysis of splice factor expression in T24 and PC3 cells
Western blot analysis was used to characterize the expression of SR proteins and hnRNP A1 in T24 and PC3 cells. As shown in Figure 6 , members of these functionally antagonistic splice factor families are abundantly expressed by both cell lines. Moreover, despite differences in their ability to process CD44 mRNAs, the overall level of expression of these various proteins appears fairly similar in T24 and PC3 cells.
Discussion
In order to succeed, a gene therapy-based approach to the treatment of cancer must not only be effective, it must also be safe and practical. Since transduction of normal tissues is a legitimate safety concern, particularly in the context of intravenously administered vectors, there are obvious benefits to be gained from developing strategies that restrict the expression and/or activity of therapeutic genes to the desired target cell population. In this regard, we have previously demonstrated that alternative splicing can be exploited as a highly specific means of targeting the expression of therapeutic genes to tumor cells expressing particular isoforms of the adhesion protein CD44. 4 The present study confirms and extends these initial findings and provides insights into the molecular mechanisms that underlie the apparent specificity of this approach. Specifically, the results obtained indicate that all cells tested, irrespective of the CD44 isoforms they express, appear capable of accurately removing the intronic sequence that separates the alternatively spliced CD44 exons v8 and v9. Indeed, emphasizing the apparent ubiquity of the required trans-acting factors, minigene constructs containing v8-v9 are appropriately processed even in cells such as K562 that lack CD44 expression (data not shown). In contrast, only cells such as PC3 that express CD44 isoforms that include exon v10 (e.g. CD44R1 and CD44R2) are capable of accurately and efficiently removing the v9-v10 intron. In T24 and other cells that express primarily the CD44 H isoform, alternative intronic splice donor and/or acceptor sites are favored resulting in the production of transcripts that retain various portions of the v9-v10 intron. Since the v9-v10 intron contains multiple stop codons in all three reading frames, translation is presumably terminated at this point preventing the formation of a functional chimeric protein. A large panel of tumor cell lines that differ in CD44 isoform expression have now been tested for their ability to splice transcripts derived pSAGE vectors and the relationship between the presence of CD44R1 and complete and accurate removal of the v9-v10 intron confirmed. Figure 5 Retention of intronic sequences within endogenous CD44 transcripts. RNA was isolated from untransfected T24 and PC3 cells and RT-PCR analysis carried out as described in the Materials and methods section using primers that correspond to CD44 exon v8 and exon v10. The pCEP4.CD44R1 plasmid was used as a control template to demonstrate the expected size of appropriately spliced transcripts in which intronic sequences are completely removed. Larger species containing retained intronic sequences are arrowed. Since promoter methylation and/or other processes may result in CD44 expression being downregulated in certain tumor types or at certain stages in tumor progression, knowledge of the trans-acting factors that control CD44 splicing would help ensure accurate identification of the subset of tumors that can be targeted using the proposed splice-activated gene expression approach. Attention in this regard has focused on members of a conserved family of ubiquitous and highly expressed RNA-binding proteins known as the SR proteins, so called because of the presence of a characteristic serine-argine-rich carboxy-terminal domain of variable length. 16, 17 SR proteins function as an essential component of the constitutive splicing machinery playing a critical role in the early stages of spliceosome assembly. Importantly, they also seem to affect the alternative splicing of many different pre-mRNA transcripts, acting in a concentration-dependent manner and combinatorial pattern to promote the use of proximal alternative 5 0 splice sites. 16, 17 A number of SR protein antagonists have also been identified. These include hnRNP A1 18 and other hnRNP A/B family members (hnRNP A1B, A2 and B1). 19 These proteins are associated with most, if not all, nascent mRNA transcripts in vivo and play an important role in RNA transport. hnRNP A1 also contributes to the regulation of alternative splicing with increasing concentrations favoring the use of distal 5 0 splice sites, while limiting hnRNP A1 expression encourages the use of proximal 5 0 splice sites. 18, 20 On the basis of these various findings, it has been proposed that the choice between intronic and exonic splice sites may be regulated by changes in the relative level of expression of SR proteins and hnRNPs 18, 20 with additional specificity being achieved if particular combinations of these antagonistic factors act preferentially on certain pre-mRNA transcripts. 16, 17, 20, 21 Although this model is attractive in its simplicity, in the present study Western blot analysis failed to demonstrate substantial differences in the levels of these two families of splicing factors in T24 and PC3 cells, suggesting that more complex mechanisms operate to determine splice site selection in the context of CD44. Of course, it is quite possible that the functional activity of SR proteins and hnRNPs may differ in the two cell lines and studies are currently underway to determine whether these molecules are differentially phosphorylated or otherwise modified in a cell-specific manner.
As shown in Figure 7 , sequence analysis indicates that both the alternative splice donor and acceptor sites located in the v9-v10 intron are a better match to the corresponding consensus sequences than the splice donor and acceptor sites located, respectively, at the 3 0 end of exon v9 and the 5 0 end of exon v10. Analysis using the SpliceSiteFinder algorithm (where a higher number represents a better match to consensus) scored the exon v9 splice donor at 74.8, while the intronic splice donor scored 85.2. Similarly, while the exon v10 splice acceptor gave a score of 84.9, the intronic splice acceptor scored 94.4. Both the exonic and intronic splice acceptor sites have consensus branch point sequences located at an appropriate distance 5 0 of their polypyrimidine tracks (Fig 7) .
Although conceptually attractive, the simple explanation that the intronic splice donor and acceptor sites are favored in CD44H-positive cells because they are a better match to consensus is argued against by the fact that the intron between exons v8 and v9 is efficiently removed in both CD44H-positive and CD44R1-positive cells despite the fact that both the splice donor and acceptor sites score lower than the corresponding exon v9 and v10 sites using the SpliceSiteFinder algorithm. Instead, the differential splicing of the v9-v10 intron in CD44H-and CD44R1-positive cells supports the existence of cellspecific factors that control the processing of CD44 premRNA transcripts. Whether such factors promote the recognition of ''weaker'' exonic splice donor and acceptor sites in CD44R1-positive cells or inhibit the recognition of the ''stronger'' intronic sites that are preferentially used in CD44H-positive cells, remains to be determined. Figure 7 Relationship of exonic and intron splice sites to consensus sequences. The exonic and intronic splice donor and acceptor sites identified in the course of the present study are shown aligned beneath the corresponding consensus sequences. Numeric values reflecting the degree of similarity to consensus were calculated using the SpliceSiteFinder algorithm and are indicated in brackets.
Galiana-Arnoux et al 22 have, however, recently demonstrated the presence within CD44 exon v9 of a splicing enhancer of approximately 30 nucleotides that binds the SR proteins 9G8, ASF/SF2 and SRp20, promoting inclusion of this particular exon. Similar splice enhancer elements have also been identified within several other alternatively spliced CD44 exons, most notably exon v5. 23 In general, the alternative splicing process tends to produce CD44 transcripts in which blocks rather than individual alternatively spliced exons are included in the final mRNA product. 24 Moreover, sequence analysis suggests that exons lying toward the 3 0 end of the variant region are often favored over those lying closer to the transcriptional start site. 24 There is also good evidence that prior splicing events can have a direct impact on subsequent reactions. Indeed, supporting the hierarchical and sequential nature of CD44 splicing, RT-PCR analysis carried out in the course of the present study revealed that the major vector-derived transcript present in T24 cells transfected with v8/v9-v10.ALP or v8-v9-v10.ALP is produced as a result of splicing between the ''strong'' splice donor and acceptor sites present within the v9-v10 intron (Fig 4c) . Since splicing between these two sites is not seen in T24 cells transfected with the equivalent v9-v10.ALP construct, it is assumed that this particular event is promoted when the v8 and v9 exons are first joined together. Perhaps the prior joining of exon v8 and v9 generates a novel site that permits the binding of factors that modulate the subsequent splicing of the adjacent v9-v10 intron. Such considerations may need to be taken into account in the design of splice-activated vectors for use in gene therapy.
It is important to emphasize that the alternative intronic splice sites identified in the course of the present study are not recognized by the splicing machinery solely in the context of isolated minigene constructs but are of probable physiologic importance. As shown in Figure 5 , RT-PCR analysis indicated the presence of retained intronic sequences within exon v8-v10-containing CD44 transcripts expressed by the CD44H-positive T24 cell line. Moreover, studies in the mouse have suggested that sites within the v9-v10 intron analogous to those identified in the present study are preferentially utilized in certain tumors resulting in the production of soluble CD44 proteins that appear to play an important role in the regulation of tumor growth and metastasis. 25 Soluble CD44 proteins generated through the preferential use of alternative splice sites within the v9-v10 intron have also been identified in the urine of patients with bladder cancer. Importantly, correlations have been noted between the presence of such proteins and disease stage and/ or prognosis.
Although this initial work has focused on v10-containing CD44 isoforms, more than 30% of human genes appear to undergo alternative splicing. 26, 27 Moreover, increased and/or abnormal splicing is often observed in malignancy 28 suggesting that splice-activated gene expression may prove broadly useful as a strategy for targeting therapeutic genes to tumor cells in vivo. For example, we have recently described a novel differentially expressed CD44 isoform that is specifically upregulated in malignant hematopoietic cells, designated CD44RC, that is generated by an alternative splicing event in which the 3 0 end of exon 2 is spliced into an internal splice acceptor site present in exon 18 . 29 This alters the subsequent reading frame, giving rise to a soluble protein with a unique COOH terminus. Other functionally important genes whose protein products are differentially spliced in normal and malignant cells include prostate-specific membrane antigen, 30 the hyaluronan-binding protein RHAMM, 31 the estrogen receptor-alpha, 32 phosphatidic acid phosphatase, 33 Pmel17 (an important regulator of melanosome precursor morphogenesis), 34 the tumor metastasis suppressor KAI1, 35 and cyclin D1. 36 Although such aberrantly spliced proteins are thought to be produced mainly as a result of mutations occurring in the cis-acting sequence elements that control RNA processing, 37 changes in the expression, function and/or distribution of required trans-acting factors have also been noted in malignant cells. 38 Taken together, these data emphasize the potential of alternative splicing as a means of targeting the expression of therapeutic genes to tumor cells in vivo. Ultimately, however, no single approach is likely to provide all of the necessary specificity, and additional benefits will undoubtedly be gained by incorporating multiple independent layers of control into vector design. While tumorspecific promoter/enhancer elements have an important role to play in this regard, narrowing down the precise cisacting sequences and trans-acting factors involved in the regulation of alternative splicing will enable the development of compact vectors that behave in a predictable fashion in a broad range of target cells.
